Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502882 | 0.91 | PPARG (0.69) | PPARG | |
| SCHEMBL470987 | 0.89 | PPARG (1.00) | PPARG | |
| SCHEMBL502892 | 0.89 | PPARG (0.85) | PPARG | |
| SCHEMBL3487409 | 0.85 | PPARG (0.83) | PPARG | |
| SCHEMBL3488549 | 0.85 | PPARG (0.87) | PPARG | |
| Hydrochloric Acid SCHEMBL3487500 | 0.85 | PPARG (1.00) | PPARG | |
| SCHEMBL3487022 | 0.84 | PPARG (1.00) | PPARG | |
| Hydrochloric Acid SCHEMBL3487188 | 0.84 | PPARG (0.90) | PPARG | |
| SCHEMBL502699 | 0.83 | PPARG (0.82) | PPARG | |
| SCHEMBL3487212 | 0.83 | PPARG (1.00) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404918-B1 | PYRIDINE DERIVATIVE AS PPARY INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2016-11-30 | — | — | EP | claimed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | claimed |
| EP-2404918-A1 | PYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-11 | — | — | EP | claimed |
| EP-2404918-B1 | PYRIDINE DERIVATIVE AS PPARY INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2404918-B1 | PYRIDINE DERIVATIVE AS PPARY INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946264-B2 | Pyridine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130204009-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130204009-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130204009-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-21 | — | — | US | disclosed |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-21 | — | — | US | disclosed |
| WO-2012033091-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | 第一三共株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2404918-A1 | PYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404918-A1 | PYRIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-11 | — | — | EP | disclosed |
| WO-2010101164-A1 | PYRIDINE DERIVATIVE | 第一三共株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130204009-A1 | PROCESS FOR PREPARING BENZOIC ACID ESTERS | HPD, CYP2B6, PAH | PPARG 323/4885 |
| US-20120029026-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | PPARG 2/4885 |
| US-20130045994-A1 | PYRIDINE DERIVATIVE | PPARD, PPARG, PPARA | PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.